Radiopharmaceutical provider Ion Beam Applications has received U.S. Food and Drug Administration (FDA) clearance for its adaPT Insight imaging software suite.
Based on a software platform developed in partnership with the University of Louvain, Belgium, adaPT Insight enables imaging and correction capabilities for the firm's ProteusOne and ProteusPlus proton therapy systems. The software is part of IBA's adaPT Treatment Suite integrated proton therapy software family, and incorporates image-guidance features such as 3D cone beam CT and stereoscopic x-ray imaging in order to provide increased accuracy in patient treatments, according to the vendor.
IBA said adaPT Insight can be fully integrated with major oncology information systems and provides 6D corrections of patient positions. The company said the software's modular architecture and workflow-based approach builds a foundation for the development of future specific image-guided proton therapy offerings.